Subregional differences in astrocytes underlie selective neurodegeneration or protection in Parkinson's disease models in culture

Aging and Cognitive FunctionsAlzheimer’s Disease

Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals

JAMA Neurol.

Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, Murray ME, Roberts RO, Vassilaki M, Lowe VJ, Machulda MM, Jones DT, Petersen RC, Jack CR Jr

doi: 10.1001/

The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain

Acta Neuropathol Commun.

Normando EM, Davis BM, De Groef L, Nizari S, Turner LA, Ravindran N, Pahlitzsch M, Brenton J, Malaguarnera G, Guo L, Somavarapu S, Cordeiro MF

doi: 10.1186/s40478-016-0346-z.

COMMENTED

Multiple Sclerosis

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Read the related editorial recommended by Dr med. Andreas Hottinger: Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?

doi: 10.1001/

Further Publications Neurology

Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease

Brain

Zarkali A, McColgan P, Ryten M, Reynolds R, Leyland LA, Lees AJ, Rees G, Weil RS

doi: 10.1093/brain/awaa270

Parkinson’s Disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

J Neurol.

Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P

doi: 10.1007/s00415-

Aging and Cognitive FunctionsAlzheimer’s Disease

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

JAMA Neurol.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative

doi: 10.1001/jamaneurol.

RECOMMENDED

Parkinson’s Disease

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Mov Disord.

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group

doi: 10.1002/mds.27492.

Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores

Neurology.

Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, Pérez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT

doi: 10.1212/

Parkinson’s Disease

Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease

JAMA Neurol.

De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT

doi: 10.1001/jamaneurol.

Related content

Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals

The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores

Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease